Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

An approach to new antiviral medicines using a combination of genomics and proteomics

10.12.2015

World-wide recurrent seasonal influenza epidemic are mainly caused by influenza A viruses. However, these are frequently resistant to currently available antiviral medications. Scientists from the Paul-Ehrlich-Institut together with international research collaborators have identified a new target protein, which can be used to help develop novel antivirals in future. This was achieved by analysing the interactions between the influenza A virus and the infected cells in humans. Cell Host Microbe reports on these research results in its online edition of 9 December.

Between two and ten million people are infected with influenza viruses, that cause seasonal annual epidemics of disease. Influenza viruses are subdivided into influenza A, B, and C and their various subtypes. Influenza A viruses often constitute the main type of the circulating influenza viruses world-wide.


Human lung carcinoma cells infected with influenza A virus (nucleus in blue). The viral proteins haemagglutinin (green) and matrix protein 2 (red) are mainly located on the plasma membrane.

Source: Center for Microscopy and Image Analysis, University of Zurich

Influenza viruses undergo rapid genetic changes, therefore, influenza vaccines are adapted to the circulating seasonal influenza viruses each year. Moreover, drugs against influenza viruses, so-called antivirals, are required to treat infected individuals and are needed as a future treatment option for the occurrence of new (influenza) viruses – especially in the event of a pandemic. Meanwhile, however, a great number of influenza A viruses have become resistant to the currently available antiviral medications.

An approach to new effective antivirals against viruses is to inhibit the interaction between the virus and its host, i.e. the affected cells in the infected individual, since viruses use human cell proteins to reproduce and proliferate. A blockage of the interaction between virus proteins and cell proteins could inhibit the reproduction of the viruses, thus treating influenza successfully.

So far, the exact mechanism of interaction of influenza A virus with human cells have not been fully understood. Extensive systems-level data are available worldwide, but are seemingly discordant.

A joint collaborative research effort between four international research groups – including the group of Dr Renate König, head of the research team “Cellular Aspects of Pathogen-Host Interactions” at the Paul-Ehrlich-Institut have succeeded in generating a biochemical “map” of essential influenza A virus/host interactions. They achieved this by combining extensive genomic (relating to genes) and proteomic (relating to proteins) data analyses.

With the help of this map, the scientists identified UBR4 (ubiquitin protein ligase E3 component n-recognin 4), a protein in human cells which is responsible for “budding”, i.e. separating the viruses from the cell membrane, the exiting of the pathogen from the cell and subsequent proliferation within and outside the body. The scientists assume that UBR4 is “borrowed” by the virus to deactivate a protection mechanism in humans using its enzymatic function.

According to the scientists, this protection mechanism is as yet not known in detail. The scientists assume that it causes degradation of the viral proteins thus stopping them from being transported to the cell membrane. Based on this model, the influenza A virus thus buys itself a safe passage to the cell membrane. A novel approach to developing new antiviral drugs against the influenza A virus could be to strengthen the above mentioned protective mechanism.

“One advantage of active substances acting on cellular (human) proteins essential for the virus is the fact that the human genome does not constantly change so that active substances should also show long-term efficacy”, as Dr. König explains. Another advantage is that drugs that target cellular proteins may be effective against quite different viruses which utilize the same human protein machinery, of course, without disrupting essential cell functions. And finally, cellular proteins as target structures have the potential to be used to enhance the efficacy of vaccines.

Original publication

Tripathi S, Pohl MO, Zhou Y, Rodriguez-Frandsen A,, Wang G, Stein DA, Moulton HM, DeJesus P, Che J, Mulder LC, Yángüez E, Andenmatten D, Pache L, Manicassamy B, Albrecht RA, Gonzalez MG, Nguyen Q, Brass A, Elledge S, White M, Shapira S, Hacohen N, Karlas A, Meyer TF, Shales M, Gatorano A, Johnson JR, Jang G, Johnson T, Verschueren E, Sanders D, Krogan N, Shaw M, König R#, Stertz S#, García-Sastre A#, Chanda SK# (2015):
Meta- and Orthogonal Integration of Influenza ‘OMICs’ Data Reveals UBR4 as a Critical Regulator of M2 Ion Channel Membrane Trafficking. Cell Host Microbe. 2015 18: 723-735.
# Co-senior authors

The Paul-Ehrlich-Institut, the Federal Institute for Vaccines and Biomedicines, in Langen near Frankfurt/Main is a senior federal authority reporting to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). It is responsible for the research, assessment, and marketing authorisation of biomedicines for human use and immunological veterinary medicinal products. Its remit also includes the authorisation of clinical trials and pharmacovigilance, i.e. recording and evaluation of potential adverse effects. Other duties of the institute include official batch control, scientific advice and inspections. In-house experimental research in the field of biomedicines and life science form an indispensable basis for the manifold tasks performed at the institute. The Paul-Ehrlich-Institut, with its roughly 800 members of staff, also has advisory functions nationally (federal government, federal states (Länder)), and internationally (World Health Organisation, European Medicines Agency, European Commission, Council of Europe etc.).

Weitere Informationen:

Publication Abstract
http://www.pei.de/EN/information/journalists-press/press-releases/2015/20-approa... - This press release on the PEI-Website

Dr. Susanne Stöcker | idw - Informationsdienst Wissenschaft

More articles from Life Sciences:

nachricht Are there sustainable solutions in dealing with dwindling phosphorus resources?
16.10.2017 | Leibniz-Institut für Nutzierbiologie (FBN)

nachricht Strange undertakings: ant queens bury dead to prevent disease
13.10.2017 | Institute of Science and Technology Austria

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

Im Focus: New nanomaterial can extract hydrogen fuel from seawater

Hybrid material converts more sunlight and can weather seawater's harsh conditions

It's possible to produce hydrogen to power fuel cells by extracting the gas from seawater, but the electricity required to do it makes the process costly. UCF...

Im Focus: Small collisions make big impact on Mercury's thin atmosphere

Mercury, our smallest planetary neighbor, has very little to call an atmosphere, but it does have a strange weather pattern: morning micro-meteor showers.

Recent modeling along with previously published results from NASA's MESSENGER spacecraft -- short for Mercury Surface, Space Environment, Geochemistry and...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

Conference Week RRR2017 on Renewable Resources from Wet and Rewetted Peatlands

28.09.2017 | Event News

 
Latest News

A single photon reveals quantum entanglement of 16 million atoms

16.10.2017 | Physics and Astronomy

The melting ice makes the sea around Greenland less saline

16.10.2017 | Earth Sciences

On the generation of solar spicules and Alfvenic waves

16.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>